A clinical trial of the "second generation" new crown vaccine aimed at solving the problem of new coronavirus mutations is about to begin

Most of the current vaccines in the study use the new coronavirus prickly protein or prickly protein's bind domain as an antigen.
Although they have shown good protection in clinical trials, the recent emergence of new coronavirus strains also shows the potential risk of this strategy, namely that genetic mutations in prickly proteins may invalidate vaccine-inspired neutral antibodies.
second-generation new crown candidate vaccine being developed by Grytstone contains additional viral antigen progestin in addition to hedgehog proteins.
its goal is not only to activate a more comprehensive strong antibody immune response, but also to activate the Immune response of CD8-positive T cells.
CD8-positive T cells are able to identify and destroy cells infected with the new coronavirus, providing another layer of protection beyond the meso-antibodies.
Gritstone used two different technology platforms to deliver new coronavirus antigens.
use adenovirus vectors for the first inoculation, while the second enhanced inoculation uses self-amplified mRNA.
the effects of adenovirus vector-stimulated median antibodies on the second vaccination.
", Gritstone's vaccine may provide more comprehensive virus protection by inducing a better combination of T-cell response and medium antibodies than the vaccines currently available.
"It's important that we move forward with the development of these next-generation vaccines, because we don't know yet whether existing vaccines that are authorized for emergency use (EUA) provide long-term immunity or prevent transmission," said Dr. Daniel Hoft, director of the Vaccine Development Center and Infectious Diseases, Allergy and Immunology at the University of St. Louis, chairman and lead researcher of Gritstone's COVID research program.
we may need vaccines that provide these additional benefits to continue to mitigate the oncoming pandemic.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
resources: s1. Program has Potential to Protect Against Mutant Variants of SARS-CoV-2. Retrieved January 19, 2021, from [2] Gritstone COVID-19 Vaccine Introduction. Retrieved January 19, 2021, from